Ask AI
CRSwNP Roundtable Module 2

CE / CME

Breaking New Ground in CRSwNP: The Biologics Landscape in CRSwNP Including Emerging Therapeutic Targets Roundtable Module 2

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: June 20, 2025

Expiration: June 19, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

What distinguishes tezepelumab from other biologic agents used or under investigation for the treatment of CRSwNP?

2.

A 47-year-old man presents with nasal congestion, anosmia, facial pressure, and nasal discharge for over 4 months despite using intranasal corticosteroids and saline irrigations. He has a history of asthma and reports worsening respiratory symptoms over the past year. Nasal endoscopy confirms bilateral nasal polyps. A recent CT scan shows extensive opacification of the paranasal sinuses. He underwent functional endoscopic sinus surgery (FESS) 2 years ago, but symptoms recurred within 12 months. His peripheral eosinophil count is elevated, and total serum IgE is 320 IU/mL.​ Which of the following is the most appropriate next step in management?​